Madrigal's Cholesterol Drug Succeeds in Mid-Stage Trial Post author:Sam Post published:February 7, 2018 Post category:BioPharma MGL-3196 was well-tolerated with primarily mild and some moderate AEs. Source: BioSpace You Might Also Like Meet the 5 Scientists Who Just Won Silicon Valley Billionaires' Breakthrough Prize December 4, 2017 Motif BioSciences, Inc. Reports Half-Year 2017 Financial Results And Operational Progress September 28, 2017 Perrigo Unveils Sale of Two Business Units August 10, 2017
Motif BioSciences, Inc. Reports Half-Year 2017 Financial Results And Operational Progress September 28, 2017
